Shattuck Labs Stock Soars on Analyst Boost | Business and Finance News

Shattuck Labs’ stock surged nearly 5% after J.P. Morgan analyst Brian Cheng upgraded the biotech firm to “overweight” with a $10 price target—potentially a 35% upside—driven by strong early data on its inflammatory bowel disease drug SL-325, poised to enter Phase Two trials this quarter. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/cc9283f37b1e693f